Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma - PubMed (original) (raw)
Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma
Avichai Shimoni et al. Br J Haematol. 2003 Aug.
Free article
Abstract
High-dose chemotherapy and autologous stem cell transplantation (SCT) have limited success in patients with refractory aggressive lymphoma. Allogeneic SCT may offer some advantage in this setting by providing graft-versus-lymphoma effect, but the relapse risk remains substantial. In this study, we evaluated the safety and efficacy of rituximab administration after SCT in patients at high-risk for post-transplant relapse, in order to reduce relapse risk. Twenty-eight patients were included with the intent to treat them with rituximab after autologous (n = 16) or allogeneic (n = 12) SCT. Twenty-four were given rituximab starting a median of 47 d post SCT. Three died of SCT complications prior to therapy. Nine patients not achieving a complete remission (CR) post SCT converted to CR with rituximab and with the onset of graft-versus-host disease (GVHD) in three. With a median follow-up of 12 months (range, 3-33 months) the estimated 2-year overall survival and disease-free survival was 85 +/- 7% and 55 +/- 13% respectively. When only those patients who were actually treated are analysed, these rates were 95 +/- 7% and 64 +/- 13% respectively. The relapse risk was 35 +/- 14%. Seven patients had recurrent neutropenia episodes associated with severe hypogammaglobulinaemia, which were further prevented with intravenous immunoglobulin. None of the 10 allogeneic SCT recipients treated with rituximab had severe GVHD. Rituximab may be an effective adjuvant therapy after SCT to reduce the relapse rate and improve the outcome in high-risk aggressive lymphoma. Larger scale comparative trials are necessary to better define its role in SCT.
Similar articles
- Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.
Pan D, Moskowitz CH, Zelenetz AD, Straus D, Kewalaramani T, Noy A, Qin J, Teruya-Feldstein J, Portlock CS. Pan D, et al. Cancer J. 2002 Sep-Oct;8(5):371-6. doi: 10.1097/00130404-200209000-00007. Cancer J. 2002. PMID: 12416894 - Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma.
Shortt J, Spencer A. Shortt J, et al. Bone Marrow Transplant. 2006 Sep;38(6):433-6. doi: 10.1038/sj.bmt.1705463. Epub 2006 Aug 7. Bone Marrow Transplant. 2006. PMID: 16892074 - Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma.
Villa D, George A, Seymour JF, Toze CL, Crump M, Lee C, Buckstein R, Stewart DA, MacDonald D, Foley R, Xenocostas A, Sabloff M, Chua N, Couture F, Larouche JF, Cohen S, Savage KJ, Connors JM, Panzarella T, Carney DA, Dickinson M, Kuruvilla J. Villa D, et al. Biol Blood Marrow Transplant. 2014 Nov;20(11):1813-8. doi: 10.1016/j.bbmt.2014.07.015. Epub 2014 Jul 18. Biol Blood Marrow Transplant. 2014. PMID: 25042735 - Allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma and in T-cell non-Hodgkin lymphoma: IQWiG Reports – Commission No. N17-02 [Internet].
Institute for Quality and Efficiency in Health Care (IQWiG). Institute for Quality and Efficiency in Health Care (IQWiG). Cologne (Germany): Institute for Quality and Efficiency in Health Care (IQWiG); 2019 Nov 19. Cologne (Germany): Institute for Quality and Efficiency in Health Care (IQWiG); 2019 Nov 19. PMID: 31790167 Free Books & Documents. Review. - Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P, Berinstein NL. Mangel J, et al. Semin Oncol. 2002 Feb;29(1 Suppl 2):56-69. Semin Oncol. 2002. PMID: 11842390 Review.
Cited by
- Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias.
McIver Z, Stephens N, Grim A, Barrett AJ. McIver Z, et al. Biol Blood Marrow Transplant. 2010 Nov;16(11):1549-56. doi: 10.1016/j.bbmt.2010.05.004. Epub 2010 May 24. Biol Blood Marrow Transplant. 2010. PMID: 20580848 Free PMC article. Clinical Trial. - Rituximab for steroid-refractory chronic graft-versus-host disease.
Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E. Cutler C, et al. Blood. 2006 Jul 15;108(2):756-62. doi: 10.1182/blood-2006-01-0233. Epub 2006 Mar 21. Blood. 2006. PMID: 16551963 Free PMC article. Clinical Trial. - Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis.
Irie E, Shirota Y, Suzuki C, Tajima Y, Ishizawa K, Kameoka J, Harigae H, Ishii T. Irie E, et al. Int J Hematol. 2010 Apr;91(3):501-8. doi: 10.1007/s12185-010-0528-6. Epub 2010 Mar 10. Int J Hematol. 2010. PMID: 20217285 - Validation of a Post-Transplant Lymphoproliferative Disorder Risk Prediction Score and Derivation of a New Prediction Score Using a National Bone Marrow Transplant Registry Database.
Lee CC, Hsu TC, Kuo CC, Liu MA, Abdelfattah AM, Chang CN, Yao M, Li CC, Wu KH, Chen TC, Gau JP, Wang PN, Liu YC, Chiou LW, Lee MY, Li SS, Chao TY, Jou ST, Chang HH. Lee CC, et al. Oncologist. 2021 Nov;26(11):e2034-e2041. doi: 10.1002/onco.13969. Epub 2021 Sep 23. Oncologist. 2021. PMID: 34506688 Free PMC article. - Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Société Française de Greffe de Moelle Osseuse et Thérapie Cellulaire and Eurocord.
Nguyen S, Achour A, Souchet L, Vigouroux S, Chevallier P, Furst S, Sirvent A, Bay JO, Socié G, Ceballos P, Huynh A, Cornillon J, Francois S, Legrand F, Yakoub-Agha I, Michel G, Maillard N, Margueritte G, Maury S, Uzunov M, Bulabois CE, Michallet M, Clement L, Dauriac C, Bilger K, Lejeune J, Béziat V, Rocha V, Rio B, Chevret S, Vieillard V. Nguyen S, et al. Bone Marrow Transplant. 2017 Oct;52(10):1428-1435. doi: 10.1038/bmt.2017.122. Epub 2017 Jun 26. Bone Marrow Transplant. 2017. PMID: 28650455 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources